Am J Transplant. 2021 Apr 17. doi: 10.1111/ajt.16607. Online ahead of print.
ABSTRACT
Solid organ transplant (SOT) recipients represent a high-risk group for all SARS-COV-2 infection-related adverse outcomes. Therefore, most European countries have established prioritization of SOTrecipients in their vaccination programs. Suboptimal vaccine efficacy to the SARS-COV-2 vaccines is anticipated; however, they have been excluded from vaccination trials. Overall response rates to other vaccines as influenza have demonstrated high, though acceptable, variability.
PMID:33864722 | DOI:10.1111/ajt.16607
